Vivaldi Coelho Rogerio 4

What Happened

• Vivaldi Coelho Rogerio, a director of Crinetics Pharmaceuticals, sold 3,000 shares of CRNX on July 2, 2026. The shares were sold in open-market transactions at $40.00 per share, generating proceeds of approximately $120,000. This was a sale (often a routine disposition) executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: July 2, 2026; Filing date: July 7, 2026 (Form 4 accession: 0001628280-26-047507).
• Price and amount: 3,000 shares at $40.00 per share — total proceeds ~$120,000.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: (F1) Sale effected automatically under a Rule 10b5-1 plan adopted December 11, 2025. (F2) Sales were open-market transactions at $40.00/share.
• Timeliness: The trade occurred July 2 and the Form 4 was filed July 7; Form 4s are generally due within two business days of the transaction, so investors may note the multi-day gap.

Context

• A 10b5-1 plan indicates this sale followed a pre-set, automated schedule rather than a discretionary trade, which can reduce the implication that the director traded on non-public information.
• Sales are common for liquidity or diversification and are generally less informative than purchases about an insider’s view of company prospects.